Roche has filed its cutting-edge rheumatoid arthritis drug Actemra for FDA approval. That's a key milestone for the antibody therapy, the first that promises to control the inflammatory response mechanism by inhibiting the interleukin-6 receptor. Most current therapies are anti-TNFs. Actemra was developed by Japan's Chugai, which is owned by Roche.
- check out the release for more info
- see the report from MarketWatch